Cubist Tells Fed. Circ. MRSA Drug Patents Are Valid
Cubist Pharmaceuticals Inc. has urged the Federal Circuit to reverse the invalidation of four patents for the antibiotic daptomycin, arguing that while it didn't discover the drug, the company developed it...To view the full article, register now.
Already a subscriber? Click here to view full article